Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p322 | Osteoporosis: evaluation and imaging | ECTS2016

The essential role of bone biochemistry in the treatment of osteoporosis with rPTH therapy: a large study of over 450 patients

Casey Miriam , Healy Martin , McCarroll Kevin , Sidique Najia , Mahon James , Fallon Nessa , Walsh Bernard , Lannon Rosaleen

The effect of recombinant parathyroid hormone therapy as an anabolic agent has delivered great success in the treatment of osteoporosis. Although a treatment response is still defined in DXA terms, initial scans can fail to detect an increase in BMD since the collagen deposited in bone may not yet have mineralized. It is key therefore that an early response is detected biochemically and the physician can be reassured that the bone is not adynamic, the patient is compliant and ...

ba0005p351 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Gender differences in presentation and outcomes in older hip fracture patients

Maher Niamh , Steen Georgina , Fallon Nessa , Browne Joseph , Walsh James Bernard , Casey Miriam

Introduction: Hip fracture is a significant health problem with 25–30% occurring in men. Outcome differences between the genders have been documented, particularly mortality rates.Aim: To prospectively investigate outcomes of elderly hip fracture patients regarding mortality, recovery of function, quality of life, incidence of osteoporosis, osteoporosis knowledge, medication adherence, nutritional status and fear of falling.Me...

ba0006p182 | (1) | ICCBH2017

Osteonecrosis results in significant long term morbidity in patients with acute lymphoblastic leukaemia

Amin Nadia , Feltbower Richard , Kinsey Sally , Vora Ajay , Mushtaq Talat , James Beki

Objectives: To determine the national prevalence, management and long term outcomes of patients who develop osteonecrosis after initiation of treatment for acute lymphoblastic leukaemia (ALL).Methods: The central trials unit for the leukaemia trial UKALL2003 identified patients with reported bone toxicity out of the 3126 patients recruited into the study. Questionnaires were sent to each relevant treatment centre requesting information about each patient...

ba0007oc18 | (1) | ICCBH2019

Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children

Arshad Fawaz , Lefley Diane , Madan Sanjeev , Fernandes James , Bishop Nick , Ottewell Penelope

Objectives: Osteogenesis imperfecta (OI) displays a heterozygous phenotype even amongst similar genotypes. It has therefore been difficult to establish a mouse model which represents clinical OI in children. By engrafting human OI bone into mice we have developed a hybrid model enabling us to investigate the efficacy of new treatments for this phenotypically diverse condition.Methods: Bone chips, that would otherwise be discarded, were collected from chi...

ba0007p180 | (1) | ICCBH2019

A retrospective review of modern spine surgery in the skeletal dysplasia population

Lovecchio Francis , Shafi Karim , Steinhaus Michael , Samuel Andre , Farmer James , Sava Maria , Carter Erin , Raggio Cathleen

Objective: Existing case series examining outcomes following spine surgery for patients with skeletal dysplasias demonstrate high rates of complications. Yet, these earlier studies are from a single institution, contain surgeries performed almost 50 years ago, and only include patients with a diagnosis of achondroplasia. The objective is to determine contemporary outcomes after spinal surgery in patients with skeletal dypslasias, focusing on complications and revisions. We pre...

ba0005p128 | Cancer and bone: basic, translational and clinical | ECTS2016

The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-γ mice

Lawson Michelle , Chantry Andrew , Paton-Hough Julia , Evans Holly , Lath Darren , Tsoumpra Maria , Lundy Mark , Dobson Roy , Quijano Michael , Kwaasi Aaron , Dunford James , Duan Xuchen , Triffit James , Mazur Adam , Jeans Gwyn , Russell Graham , Ebetino Hal

Bisphosphonates are used in the treatment of a variety of diseases with skeletal complications. With the development of more potent compounds, there is the potential for further improvement. One concept is to use compounds with a reduced affinity for bone, reducing their long-term retention and possible adverse events, as well as potentially enhancing their non-skeletal benefits. We hypothesise that a highly potent bisphosphonate with low bone affinity, known as OX14, will be ...

ba0001pp144 | Cancer and bone: basic, translational and clinical | ECTS2013

Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors

Lamoureux Francois , Baud'huin Marc , Rodriguez Lidia , Jacques Camille , Berreur Martine , Bradner James E , Redini Francoise , Heymann Dominique , Ory Benjamin

Osteosarcoma is the most frequent primary bone tumor that develops mainly in young adults. The survival rate at 5 years is below 30% for patients with poor response to treatment or with metastasis.The histones modifications are of critical importance in maintaining the transcription program of both normal and tumor cells. The bromodomain and extra-terminal domain (BET) protein family is an important class of ‘histone reading protein’ capable to...

ba0002p152 | (1) | ICCBH2013

Zinc supplementation improves bone density in young adults with thalassemia

Fung Ellen B , Kwiatkowski Janet L , Huang James N , Gildengorin Ginny , King Janet C , Queisser Anne C , Vichinsky Elliott P

Poor bone mineralization remains a major health problem in patients with Thal and has been linked to functional zinc deficiency despite adequate dietary intake. The global etiology of poor bone mineralization includes inadequate dietary intake of calcium and vitamin D, endocrinopathies leading to disturbed calcium homeostasis, dysregulation of the GH–IGF1 axis, and delayed puberty, all resulting in limited growth, decreased bone formation and increased bone resorption. Th...

ba0003oc4.4 | Genetics of bone disease | ECTS2014

Variants in RIN3 predispose to Paget's disease of bone

Vallet Maheva , Sophocleous Antonia , Warner Jon , Morris Stewart W , Wilson James F , Albagha Omar ME , Ralston Stuart H

Background: Paget’s disease of Bone (PDB) has a strong genetic component and a candidate locus for the disease has been identified on chromosome 14q32, tagged by rs10498635 located within RIN3 (Albagha et al, Nat Genet 2011). RIN3 encodes a protein that acts as a guanine nucleotide exchange factor for Rab5b and Rab31. Here we investigated the candidacy of RIN3 as a predisposing gene for PDB.Methods: We studied expression of RIN3 by quantita...